A much-publicised report suggests that white Britons’ brain tumour survival rates are lower than other ethnicities. But analysing the ethnicities categories used, and considering the diversity of the “brain tumour” label, complicates the picture, as the ‘Dismal Disease’ of Glioblastoma continues to confound.
The Global Summit systematic review claims that spinal manipulation therapy is not effective in preventing any non-musculoskeletal disorders. But a breakaway group has challenged their findings, in part based on my arguments regarding evidence hierarchies. Are they correct? Does my critique undermine the Global Summit review? If so, does the evidence base favour chiropractic?
Political interests configure the stories we tell with data. Closing the gap in attainment between disadvantaged students and their advantaged contemporaries is pivotal to an agenda to use education as a positive social force. But both the measurement and representation of this gap is politicised, skewed and open to manipulation. This paper shows how two organisations with inverse aims represent—and misrepresent—their measure of the attainment gap to portray diametric trajectories in the pursuit of equal attainment.
Pressure mounts upon equalities minister Kemi Badenoch to resign over the UK government’s failure to ban conversion therapies. Attention has focused on the government’s failure to publish research commissioned in 2018. But evidence about whether conversion therapy works is irrelevant: conversion therapy is not a medical intervention.
The database of evidence hierarchies has been updated based on a new systematic review of the medical literature, and now contains over 195 hierarchies.
I have written extensively on hierarchies of evidence in evidence-based medicine. The origin story of hierarchies of evidence is a little contentious. Several sources in EBM cite Campbell and Stanley’s 1963 classic “Experimental and Quasi-experimental Designs for Research” as containing the first hierarchy, or at least the germ of the …
“I think the challenge is really that we still, not only in glioblastoma, but in oncology at large, treat the majority of patients with a one-size-fits-all approach.” — Roger Stupp Blockbuster drugs are rare. To be a blockbuster, a drug must shift over $1bn worth in one year. There …
Recently, I wrote about a new machine learning model called GPT-2 which was conspicuously not released by OpenAI. GPT-2 is a massive language model which can be used to generate often highly convincing text when given a prompt. Using the ‘attention’ framework, the language model is able to produce compelling …
Take a look at the following snippets from descriptions of clinical trials, thinking about how you’d rate the quality and strength of the evidence that comes from each: 1: We conducted a clinical trial in which erythropoietin (EPO) administration was administered daily to patients with severe acne resulting in clinically significant …
Do you have an idea of what makes good medical evidence in your mind? Do you have ideas about the kind of evidence you’d pay attention to, and the kind of evidence you can safely disregard? Or ideas about the evidence that would strongly sway your beliefs and actions, and …
